With its headquarters in the heart of Silicon Valley and offices around the world, Hitachi Chemical Diagnostics is a global leader in in vitro allergy diagnostics with a legacy of innovation. Hitachi Chemical Diagnostics was the first company to introduce a multiple in vitro diagnostic test for allergies and one of the first to introduce a chemiluminescent assay system for the detection of IgE antibodies. The company holds many in vitro allergy testing technology patents and continues to pioneer advancements in the field.

Hitachi Chemical Diagnostics, an integral member of the Hitachi Group, works with industry leaders, laboratories and distributors around the world to provide the medical community access to the latest in vitro allergy testing technology. Hitachi Chemical Diagnostics is committed to innovation, quality, and the strength of the Hitachi brand. Our products are marketed in over 40 countries worldwide. To learn more about Hitachi Chemical Diagnostics and CLA, please contact us or your local representative, or visit us on the web at www.hcdiagnostics.com.

United States Office
630 Clyde Court
Mountain View, CA 94043-2239
650.961.5501
800.233.6278
www.hcdiagnostics.com

European Office
Hitachi Chemical Diagnostics, Inc.
Hitachi Europe Ltd.
Whitebrook Park
Lower Cookham Road
Maidenhead, Berkshire, SL6 8YA
United Kingdom
44 (0) 1628.585.590

CLA is a registered trademark and CLA-1 is a trademark of Hitachi Chemical Diagnostics, Inc., in the United States and/or other countries worldwide.

Allergies are the 6th leading cause of chronic disease in the United States, costing the health care system $18 billion annually.1

While once considered more costly than skin testing, modern screening methods in vitro allergy testing no more costly than skin testing. Many insurers have recognized the cost-efficiency and diagnostic accuracy of in vitro allergy testing technology. Accurate test results offer good correlation with skin testing. Access to the latest technology, one of the most sensitive detection systems available, is the fundamental component of the system. Each device contains up to 36 cellulose threads, each bound with a selected allergen.

The CLA Allergen-Specific IgE Assay

The system, which consists mainly of the CLA Pette, and the CLA™ Luminometer, simultaneously measures the severity of a patient’s allergic reaction to up to 36 different allergens using a single 1.5 ml serum sample.

The CLA Pette, a small plastic device, is the fundamental component of the system. Each device contains up to 36 cellulose threads, each bound with a selected allergen.

Contraposed to the CLA Pette, the CLA™ Luminometer com- pletes the allergy testing system. This bench-top instrument reads prepared CLA Pettes, measuring the amount of chemiluminescent light emitted by the reaction to each allergen. In less than ten minutes, it can analyze up to 185 allergens. The instrument automatically prints a complete report that lists the tested allergens and the severity of the patient’s response to each.

For a board-certified allergist is available to discuss test results, treatment options and other aspects of allergic disease. Educational materials for patients are also available.

While one considered more costly than skin testing, modern screening methods in vitro allergy testing no more costly than skin testing. Many insurers have incorporated these cost-saving screens into their coverage guidelines.¹


Helping the Medical Community
Hitachi Quality
Accurate test results offer good correlation with skin testing. Access to the latest in vitro allergy testing technology.

Objective Analysis
Up to 36 specific IgE results—optimized with the most regional or categorically prevalent—allergens—from a 1.5 ml serum sample.

Easy to Use
- CLA Immobilizer: Complexity Complexity system requires minimal training and provides plenty of "walk-away" data for staff to perform other duties.
- Potential advantages of in vitro assays (includes): diagnosis of inhalant allergy in selected patients in whom skin tests cannot be performed.

Easily incorporated with existing licensing, personal and space. Low start-up costs and incremental revenue help grow a physician’s practice.

A less intrusive technique that can be performed without stopping current medications and decreases waste.

Potential advantages of in vitro assays (includes):
- diagnosis of inhalant allergy in selected patients in whom skin tests cannot be performed.
- Food panels – commonly ingested foods such as peanut, milk, tomato, soybean, wheat and others.
- Combination panels – up to 36 of the most prevalent food and inhalant allergens overall.

The pre-labeled panel format simplifies testing and reduces set-up time. It also eliminates inventory of individual allergens and decreases waste.

The CLA Allergen-Specific IgE Assay

The system, which consists mainly of the CLA Pette, and the CLA™ Luminometer, simultaneously measures the severity of a patient’s allergic reaction to up to 36 different allergens using a single 1.5 ml serum sample.

The CLA Pette, a small plastic device, is the fundamental component of the system. Each device contains up to 36 cellulose threads, each bound with a selected allergen.

Contraposed to the CLA Pette, the CLA™ Luminometer com- pletes the allergy testing system. This bench-top instrument reads prepared CLA Pettes, measuring the amount of chemiluminescent light emitted by the reaction to each allergen. In less than ten minutes, it can analyze up to 185 allergens. The instrument automatically prints a complete report that lists the tested allergens and the severity of the patient’s response to each.

“The CLA assay for allergen specific IgE offers reliable results correlated with skin test results. Potential advantages of in vitro assays (includes) diagnosis of inhalant allergy in selected patients in whom skin tests cannot be performed.”


While once considered more costly than skin testing, modern screening methods in vitro allergy testing no more costly than skin testing. Many insurers have incorporated these cost-saving screens into their coverage guidelines.²


The CLA-1 Luminometer performs a self-diagnostic each time it is powered up to ensure correct results. FDA-cleared and CE-marked, it has shown consistent, reliable performance in laboratories around the world.

The system uses Hitachi’s patented chemiluminescent technology, one of the most sensitive detection systems available. The assay for the detection of very low levels of IgE in patient serum. Hitachi also holds patents on the CLA Pette and its binding technology.

The CLA Allergen-Specific IgE Assay covers allergy patients worldwide, so each panel is designed to be geographically specific. Physicians simply select the panel that’s most appropriate for their patient.

- Inhalant panels – pollen, dust, molds and other airborne allergens.
- Food panels – commonly ingested foods such as peanut, milk, tomato, soy, wheat and other foods.
- Combination panels – up to 36 of the most prevalent food and inhalant allergens overall.

The pre-labeled panel format simplifies testing and reduces set-up time. It also eliminates inventory of individual allergens and decreases waste.

Obtaining accurate test results is essential in current healthcare environment. A less intrusive technique that can be performed without stopping current medications. A less intrusive technique that can be performed without stopping current medications. A less intrusive technique that can be performed without stopping current medications.

While once considered more costly than skin testing, modern screening methods in vitro allergy testing no more costly than skin testing. Many insurers have incorporated these cost-saving screens into their coverage guidelines.

The CLA Allergen-Specific IgE Assay

The system, which consists mainly of the CLA Pette, and the CLA™ Luminometer, simultaneously measures the severity of a patient’s allergic reaction to up to 36 different allergens using a single 1.5 ml serum sample.

The CLA Pette, a small plastic device, is the fundamental component of the system. Each device contains up to 36 cellulose threads, each bound with a selected allergen.

Contraposed to the CLA Pette, the CLA™ Luminometer com- pletes the allergy testing system. This bench-top instrument reads prepared CLA Pettes, measuring the amount of chemiluminescent light emitted by the reaction to each allergen. In less than ten minutes, it can analyze up to 185 allergens. The instrument automatically prints a complete report that lists the tested allergens and the severity of the patient’s response to each.

The CLA Allergen-Specific IgE Assay

The system, which consists mainly of the CLA Pette, and the CLA™ Luminometer, simultaneously measures the severity of a patient’s allergic reaction to up to 36 different allergens using a single 1.5 ml serum sample.

The CLA Pette, a small plastic device, is the fundamental component of the system. Each device contains up to 36 cellulose threads, each bound with a selected allergen.

Contraposed to the CLA Pette, the CLA™ Luminometer com- pletes the allergy testing system. This bench-top instrument reads prepared CLA Pettes, measuring the amount of chemiluminescent light emitted by the reaction to each allergen. In less than ten minutes, it can analyze up to 185 allergens. The instrument automatically prints a complete report that lists the tested allergens and the severity of the patient’s response to each.

The CLA Allergen-Specific IgE Assay

The system, which consists mainly of the CLA Pette, and the CLA™ Luminometer, simultaneously measures the severity of a patient’s allergic reaction to up to 36 different allergens using a single 1.5 ml serum sample.

The CLA Pette, a small plastic device, is the fundamental component of the system. Each device contains up to 36 cellulose threads, each bound with a selected allergen.

Contraposed to the CLA Pette, the CLA™ Luminometer com- pletes the allergy testing system. This bench-top instrument reads prepared CLA Pettes, measuring the amount of chemiluminescent light emitted by the reaction to each allergen. In less than ten minutes, it can analyze up to 185 allergens. The instrument automatically prints a complete report that lists the tested allergens and the severity of the patient’s response to each.

The CLA Allergen-Specific IgE Assay

The system, which consists mainly of the CLA Pette, and the CLA™ Luminometer, simultaneously measures the severity of a patient’s allergic reaction to up to 36 different allergens using a single 1.5 ml serum sample.

The CLA Pette, a small plastic device, is the fundamental component of the system. Each device contains up to 36 cellulose threads, each bound with a selected allergen.

Contraposed to the CLA Pette, the CLA™ Luminometer com- pletes the allergy testing system. This bench-top instrument reads prepared CLA Pettes, measuring the amount of chemiluminescent light emitted by the reaction to each allergen. In less than ten minutes, it can analyze up to 185 allergens. The instrument automatically prints a complete report that lists the tested allergens and the severity of the patient’s response to each.
One out of every five people suffers from some form of allergy. Treating these allergies can be a challenge, but first an accurate diagnosis must be made.

In today’s cost-conscious healthcare environment, a doctor’s ability to refer allergy patients to a specialist may be diminished. Patients also expect efficient, high quality diagnosis that allows prompt and effective health management. Always known for technology and reliability, Hitachi offers the medical community an alternative means of diagnosing allergy in a timely manner and at a significantly lower cost than has traditionally been available. We are proud to present an accurate, easy to use serum test for allergy—the CLA Allergen-Specific IgE Assay. Used as part of an initial allergy evaluation, the information obtained allows optimal patient management by avoiding unnecessary and costly referrals of non-allergic patients, while allergic patients can be treated sooner and more effectively.

The CLA Allergen-Specific IgE Assay

The system, which consists mainly of the CLA Pette and the CLA-1™ Luminometer, simultaneously measures the severity of a patient’s allergic reaction to up to 36 different allergens using a single 1.5 ml serum sample.

The CLA Pette, a small plastic device, is the fundamental component of the system. Each device contains up to 36 selective threads, each bound with a selected allergen.

Contrapoint to the CLA Pette, the CLA-1™ Luminometer completes the allergy testing system. This bench-top instrument reads prepared CLA Pettes, measuring the amount of chemiluminescent light emitted by the reaction to each allergen. In less than ten minutes, it can analyze up to 185 allergens. The instrument automatically prints a complete report that lists the tested allergens and the severity of the patient’s reaction to each.

“...the CLA assay for allergen specific IgE offers reliable results corresponding with skin test results.”


Potential advantages of in vitro assays (include)

• Making diagnosis of patients with odd or rare nonspecific symptoms
• Allergy patients with positive skin test reactions and negative blood testing
• Allergy patients with negative skin test reactions and positive blood testing
• Allergy patients with unconfirmed diagnosis
• In which skin testing is contraindicated

The CLA-1 Luminometer performs a self-diagnostic each time it is powered up to ensure correct results. FDA cleared and CE marked, it has shown consistent, reliable performance in laboratories around the world.

The system uses Hitachi’s patented chemiluminescent technology, one of the most sensitive detection systems available. This allows for the detection of very low levels of IgE in patient serum. Hitachi also holds patents on the CLA Pette and its backing technology.

The CLA Allergen-Specific IgE Assay covers allergy patients worldwide, so each panel is designed to be geographically specific. Physicians simply select the panel that’s most appropriate for their patient.

• Inhalant panels—pollen, dust, mites and other airborne allergens.
• Food panels—commonly ingested foods such as peanut, milk, tomato, soybean, wheat and others.
• Combination panel—up to 36 of the most prevalent food and inhalant allergens overall.

The pre-labeled panel format simplifies testing and reduces set-up time. It also eliminates inventory of individual allergens and decreases waste.

While once considered more costly than skin testing, modern screening methods make in vitro allergy testing no more costly than skin testing. Many insurers have incorporated these cost-saving screens into their coverage guidelines.

Given their respective trajectories for technological advancement, quantification and quality control, in vitro testing may offer the more standardized approach (vs. SPT).*

Objective Analysis

The Alios Reference Laboratory has one function only: allergy testing. Physicians simply send their patients’ sera to us. We will select the CLA Allergen-Specific IgE Assay panel of their choice.

Quick Turnaround

The laboratory provides request forms, pre-paid overnight express mailers and serum vials to all its customers at no charge. In approximately three working days, physicians receive a precise, objective analysis of the patient’s reaction to each allergen.

Alios Reference Laboratory

Hitachi Chemical Diagnostics is committed to improving the lives of allergy patients. In addition to its proven product line, the company also offers extensive service and support with its Alios Reference Laboratory—an ideal alternative for physicians who want to provide their patients with a less invasive, world-class allergy diagnosis when internal testing facilities are not available.

Consultation & Education

A board-certified allergist is available to discuss test results, treatment options and other aspects of allergic disease. The lab also provides educational materials and patient history forms.

* To IPH: Changing perceptions of allergy risks and patient: N. Board on Disability, National can no longer be viewed as a luxury. The focus must be on the lives of allergy patients, not the cost. This is the core message of the Allergy Testing Task Force’s report on the current status of allergy testing in the United States. The American Journal of Managed Care, July 1998, Vol. 7, No. 4.

** To IPH: Changing perceptions of allergy risks and patient: N. Board on Disability, National can no longer be viewed as a luxury. The focus must be on the lives of allergy patients, not the cost. This is the core message of the Allergy Testing Task Force’s report on the current status of allergy testing in the United States. The American Journal of Managed Care, July 1998, Vol. 7, No. 4.
One out of every five people suffers from some form of allergy.5 Treating these allergies can be a challenge, but first an accurate diagnosis must be made.

In today's cost-conscious healthcare environment, a doctor's ability to refer allergy patients to a specialist may be diminished. Patients also prefer efficient, high-quality diagnostic tests that allow prompt and effective health management.

Always known for technology and reliability, Hitachi offers the medical community an alternative means of diagnosing allergy in a timely manner and at a significantly lower cost than has traditionally been available. We are proud to present an accurate, easy to use serum test for allergy—the CLA Allergen-Specific IgE Assay.

The CLA Allergen-Specific IgE Assay

The system, which consists mainly of the CLA Petta and the CLA-1™ Luminometer, simultaneously measures the severity of a patient's allergic reaction to up to 36 different allergens using a single 1.5 ml serum sample.

The CLA Petta, a small plastic device, is the fundamental component of the system. Each device contains up to 36 colloidal threads, each bound with a selected allergen.

Counterpart to the CLA Petta, the CLA-1 Luminometer completes the allergy testing system. This bench-top instrument reads prepared CLA Pettes, measuring the amount of chemiluminescent light emitted by the reaction to each allergen. In less than ten minutes, it can analyze up to 185 allergens. The instrument automatically prints a complete report that lists the tested allergens and the severity of the patient's response to each.

“The CLA assay for allergen specific IgE offers reliable results concordant with skin tests.”


Potential advantages of in-vitro assays (include) diagnosing inhalant allergy in selected patients in whom skin tests cannot be performed.6

While once considered more costly than skin testing, modern screening methods make in vitro allergy testing no more costly than skin testing. Many insurers have incorporated these cost-saving screens into their coverage guidelines.7

Given their respective trajectories for technological advancement, quantification and quality control, in vitro testing may offer the more standardized approach (vs. SPT).8

While once considered more costly than skin testing, modern screening methods make in vitro allergy testing no more costly than skin testing. Many insurers have incorporated these cost-saving screens into their coverage guidelines.7

Given their respective trajectories for technological advancement, quantification and quality control, in vitro testing may offer the more standardized approach (vs. SPT).8
With its headquarters in the heart of Silicon Valley and offices around the world, Hitachi Chemical Diagnostics is a global leader in in vitro allergy diagnostics with a legacy of innovation. Hitachi Chemical Diagnostics was the first company to introduce a multiple in vitro diagnostic test for allergies and one of the first to introduce a chemiluminescent assay system for the detection of IgE antibodies. The company holds many in vitro allergy testing technology patents and continues to pioneer advancements in the field.

Hitachi Chemical Diagnostics, an integral member of the Hitachi Group, works with industry leaders, laboratories and distributors around the world to provide the medical community access to the latest in vitro allergy testing technology. Hitachi Chemical Diagnostics is committed to innovation, quality, and the strength of the Hitachi brand. Our products are marketed to over 40 countries worldwide. To learn more about Hitachi Chemical Diagnostics and CLA, please contact us or your local representative, or visit us on the web at www.hcdiagnostics.com.

United States Office
630 Clyde Court
Mountain View
CA 94043-2239
650.961.5501
800.233.6278
www.hcdiagnostics.com

European Office
Hitachi Chemical Diagnostics, Inc.
Whitebrook Park
Lower Cookham Road
Maidenhead, Berkshire, SL6 8YA
United Kingdom
44 (0) 1628.585.590

CLA® is a registered trademark and CLA-1 is a trademark of Hitachi Chemical Diagnostics, Inc., in the United States and/or other countries worldwide.

Allergies are the 6th leading cause of chronic disease in the United States, costing the health care system $18 billion annually.1

With its headquarters in the heart of Silicon Valley and offices around the world, Hitachi Chemical Diagnostics is a global leader in in vitro allergy diagnostics with a legacy of innovation. Hitachi Chemical Diagnostics was the first company to introduce a multiple in vitro diagnostic test for allergies and one of the first to introduce a chemiluminescent assay system for the detection of IgE antibodies. The company holds many in vitro allergy testing technology patents and continues to pioneer advancements in the field.

Hitachi Chemical Diagnostics, an integral member of the Hitachi Group, works with industry leaders, laboratories and distributors around the world to provide the medical community access to the latest in vitro allergy testing technology. Hitachi Chemical Diagnostics is committed to innovation, quality, and the strength of the Hitachi brand. Our products are marketed to over 40 countries worldwide. To learn more about Hitachi Chemical Diagnostics and CLA, please contact us or your local representative, or visit us on the web at www.hcdiagnostics.com.